Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells
During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psor...
Gespeichert in:
| Veröffentlicht in: | Molecular medicine reports 2020-07, Vol.22 (1), p.507-515 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 515 |
|---|---|
| container_issue | 1 |
| container_start_page | 507 |
| container_title | Molecular medicine reports |
| container_volume | 22 |
| creator | Vazquez-Sanchez, Ernesto A. Mendoza-Figueroa, Jose S. Gutierrez-Gonzalez, Guadalupe Zapi-Colin, Luis A. Torales-Cardena, Azael Briseno-Lugo, Paola E. Diaz-toala, Ivan Cancino-Diaz, Juan C. Perez-Tapia, Sonia M. Cancino-Diaz, Mario E. Gomez-Chavez, Fernando Rodriguez-Martinez, Sandra |
| description | During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non-steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor-alpha, interleukin (IL)-17-A and IL-12/IL-23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans-endothelial migrationin vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis. |
| doi_str_mv | 10.3892/mmr.2020.11128 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2409585053</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A629604871</galeid><sourcerecordid>A629604871</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-4d3de9b38ba08667be431a62bb3d9899563fd45c3fb5a8c541512f74180a7a623</originalsourceid><addsrcrecordid>eNqNkk1rFTEUhgdRbK1uXUrApcw1nzOZjVCuHxUKulC3IZOcuT1lJpkmM1Z_jX_V3LaWFrqQhOTk5DkvOeGtqpeMboTu-NtpShtOOd0wxrh-VB2ytmO1oFQ-vol517UH1bOczyltFFfd0-pAcNG2LZOH1Z8TmBc7lwU9kJOvgli3ZGLLJHNcICwEwxn2uMRE4kDg1wwJp5K3I8EJL1acoq8x-NWBJ9OaMACZc0xoMxaV4As2g4dMljMgS7Ih1xB8LKcRi8iEu2QXjGEvP8UQw-pGsIk4GMf8vHoy2DHDi5v9qPr-8cO37Ul9-uXT5-3xae0UF0stvfDQ9UL3luqmaXuQgtmG973wne461YjBS-XE0CurnZJMMT60kmlq28KJo6q-1s2XMK-9mUuTNv020aJ5jz-OTUw7M-JqWNM2Shb-3TVf4Am8Kx-S7Hiv7P5NwDOziz9Ny6WWWhSB1zcCKV6skBdzHtcUSo-GS9oprai6Q-3sCAbDEIuYmzA7c9zwrqFSt6xQmweoMjxM6GKAAUv-oQKXYs4JhtuHM2r2vjLFV2bvK3Plq1Lw6m67t_g_IxXgzTVwCX0cskMIDm4xSqmSnOtO7aN9W_r_6S0uV_7YxjUs4i-RkO0T</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2409585053</pqid></control><display><type>article</type><title>Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>SWEPUB Freely available online</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Alma/SFX Local Collection</source><creator>Vazquez-Sanchez, Ernesto A. ; Mendoza-Figueroa, Jose S. ; Gutierrez-Gonzalez, Guadalupe ; Zapi-Colin, Luis A. ; Torales-Cardena, Azael ; Briseno-Lugo, Paola E. ; Diaz-toala, Ivan ; Cancino-Diaz, Juan C. ; Perez-Tapia, Sonia M. ; Cancino-Diaz, Mario E. ; Gomez-Chavez, Fernando ; Rodriguez-Martinez, Sandra</creator><creatorcontrib>Vazquez-Sanchez, Ernesto A. ; Mendoza-Figueroa, Jose S. ; Gutierrez-Gonzalez, Guadalupe ; Zapi-Colin, Luis A. ; Torales-Cardena, Azael ; Briseno-Lugo, Paola E. ; Diaz-toala, Ivan ; Cancino-Diaz, Juan C. ; Perez-Tapia, Sonia M. ; Cancino-Diaz, Mario E. ; Gomez-Chavez, Fernando ; Rodriguez-Martinez, Sandra</creatorcontrib><description>During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non-steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor-alpha, interleukin (IL)-17-A and IL-12/IL-23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans-endothelial migrationin vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.</description><identifier>ISSN: 1791-2997</identifier><identifier>ISSN: 1791-3004</identifier><identifier>EISSN: 1791-3004</identifier><identifier>DOI: 10.3892/mmr.2020.11128</identifier><identifier>PMID: 32377714</identifier><language>eng</language><publisher>ATHENS: Spandidos Publ Ltd</publisher><subject>Alefacept ; Analysis ; Animal models ; Animals ; Antibodies ; Antigens ; Antiviral drugs ; Biological products ; Cell adhesion ; Cell Line ; Cloning ; Dendritic cells ; Deoxyribonucleic acid ; Disease Models, Animal ; DNA ; Drug development ; E coli ; EDTA ; Endothelial cells ; Endothelial Cells - cytology ; Endothelial Cells - drug effects ; Endothelial Cells - pathology ; Endothelium ; Female ; Golimumab ; Helper cells ; Humans ; Imiquimod ; Inflammation ; Interleukin 12 ; Interleukin 23 ; Interleukins ; Leukocyte migration ; Leukocytes (mononuclear) ; Leukocytes, Mononuclear - cytology ; Leukocytes, Mononuclear - drug effects ; Leukocytes, Mononuclear - pathology ; Life Sciences & Biomedicine ; Lymphocytes T ; Lymphoid cells ; Macrophages ; Medicine, Research & Experimental ; Metastases ; Mice ; Mice, Inbred BALB C ; Monoclonal antibodies ; Myeloid cells ; Neutrophils ; Oligopeptides - chemistry ; Oligopeptides - pharmacology ; Oligopeptides - therapeutic use ; Oncology ; Patients ; Peptides ; Phage display ; Phototherapy ; Proteins ; Psoriasis ; Psoriasis - chemically induced ; Psoriasis - drug therapy ; Psoriasis - pathology ; Research & Experimental Medicine ; Science & Technology ; Skin ; Therapeutic applications ; Transendothelial and Transepithelial Migration - drug effects ; Tumor necrosis factor ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α</subject><ispartof>Molecular medicine reports, 2020-07, Vol.22 (1), p.507-515</ispartof><rights>COPYRIGHT 2020 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2020</rights><rights>Copyright: © Vázquez-Sánchez et al. 2020</rights><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>2</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000542289500053</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c523t-4d3de9b38ba08667be431a62bb3d9899563fd45c3fb5a8c541512f74180a7a623</citedby><cites>FETCH-LOGICAL-c523t-4d3de9b38ba08667be431a62bb3d9899563fd45c3fb5a8c541512f74180a7a623</cites><orcidid>0000-0002-2318-2463 ; 0000-0002-2500-5954</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,554,782,786,887,27933,27934,28257</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32377714$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-167654$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Vazquez-Sanchez, Ernesto A.</creatorcontrib><creatorcontrib>Mendoza-Figueroa, Jose S.</creatorcontrib><creatorcontrib>Gutierrez-Gonzalez, Guadalupe</creatorcontrib><creatorcontrib>Zapi-Colin, Luis A.</creatorcontrib><creatorcontrib>Torales-Cardena, Azael</creatorcontrib><creatorcontrib>Briseno-Lugo, Paola E.</creatorcontrib><creatorcontrib>Diaz-toala, Ivan</creatorcontrib><creatorcontrib>Cancino-Diaz, Juan C.</creatorcontrib><creatorcontrib>Perez-Tapia, Sonia M.</creatorcontrib><creatorcontrib>Cancino-Diaz, Mario E.</creatorcontrib><creatorcontrib>Gomez-Chavez, Fernando</creatorcontrib><creatorcontrib>Rodriguez-Martinez, Sandra</creatorcontrib><title>Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells</title><title>Molecular medicine reports</title><addtitle>MOL MED REP</addtitle><addtitle>Mol Med Rep</addtitle><description>During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non-steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor-alpha, interleukin (IL)-17-A and IL-12/IL-23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans-endothelial migrationin vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.</description><subject>Alefacept</subject><subject>Analysis</subject><subject>Animal models</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Antiviral drugs</subject><subject>Biological products</subject><subject>Cell adhesion</subject><subject>Cell Line</subject><subject>Cloning</subject><subject>Dendritic cells</subject><subject>Deoxyribonucleic acid</subject><subject>Disease Models, Animal</subject><subject>DNA</subject><subject>Drug development</subject><subject>E coli</subject><subject>EDTA</subject><subject>Endothelial cells</subject><subject>Endothelial Cells - cytology</subject><subject>Endothelial Cells - drug effects</subject><subject>Endothelial Cells - pathology</subject><subject>Endothelium</subject><subject>Female</subject><subject>Golimumab</subject><subject>Helper cells</subject><subject>Humans</subject><subject>Imiquimod</subject><subject>Inflammation</subject><subject>Interleukin 12</subject><subject>Interleukin 23</subject><subject>Interleukins</subject><subject>Leukocyte migration</subject><subject>Leukocytes (mononuclear)</subject><subject>Leukocytes, Mononuclear - cytology</subject><subject>Leukocytes, Mononuclear - drug effects</subject><subject>Leukocytes, Mononuclear - pathology</subject><subject>Life Sciences & Biomedicine</subject><subject>Lymphocytes T</subject><subject>Lymphoid cells</subject><subject>Macrophages</subject><subject>Medicine, Research & Experimental</subject><subject>Metastases</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monoclonal antibodies</subject><subject>Myeloid cells</subject><subject>Neutrophils</subject><subject>Oligopeptides - chemistry</subject><subject>Oligopeptides - pharmacology</subject><subject>Oligopeptides - therapeutic use</subject><subject>Oncology</subject><subject>Patients</subject><subject>Peptides</subject><subject>Phage display</subject><subject>Phototherapy</subject><subject>Proteins</subject><subject>Psoriasis</subject><subject>Psoriasis - chemically induced</subject><subject>Psoriasis - drug therapy</subject><subject>Psoriasis - pathology</subject><subject>Research & Experimental Medicine</subject><subject>Science & Technology</subject><subject>Skin</subject><subject>Therapeutic applications</subject><subject>Transendothelial and Transepithelial Migration - drug effects</subject><subject>Tumor necrosis factor</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><issn>1791-2997</issn><issn>1791-3004</issn><issn>1791-3004</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>D8T</sourceid><recordid>eNqNkk1rFTEUhgdRbK1uXUrApcw1nzOZjVCuHxUKulC3IZOcuT1lJpkmM1Z_jX_V3LaWFrqQhOTk5DkvOeGtqpeMboTu-NtpShtOOd0wxrh-VB2ytmO1oFQ-vol517UH1bOczyltFFfd0-pAcNG2LZOH1Z8TmBc7lwU9kJOvgli3ZGLLJHNcICwEwxn2uMRE4kDg1wwJp5K3I8EJL1acoq8x-NWBJ9OaMACZc0xoMxaV4As2g4dMljMgS7Ih1xB8LKcRi8iEu2QXjGEvP8UQw-pGsIk4GMf8vHoy2DHDi5v9qPr-8cO37Ul9-uXT5-3xae0UF0stvfDQ9UL3luqmaXuQgtmG973wne461YjBS-XE0CurnZJMMT60kmlq28KJo6q-1s2XMK-9mUuTNv020aJ5jz-OTUw7M-JqWNM2Shb-3TVf4Am8Kx-S7Hiv7P5NwDOziz9Ny6WWWhSB1zcCKV6skBdzHtcUSo-GS9oprai6Q-3sCAbDEIuYmzA7c9zwrqFSt6xQmweoMjxM6GKAAUv-oQKXYs4JhtuHM2r2vjLFV2bvK3Plq1Lw6m67t_g_IxXgzTVwCX0cskMIDm4xSqmSnOtO7aN9W_r_6S0uV_7YxjUs4i-RkO0T</recordid><startdate>20200701</startdate><enddate>20200701</enddate><creator>Vazquez-Sanchez, Ernesto A.</creator><creator>Mendoza-Figueroa, Jose S.</creator><creator>Gutierrez-Gonzalez, Guadalupe</creator><creator>Zapi-Colin, Luis A.</creator><creator>Torales-Cardena, Azael</creator><creator>Briseno-Lugo, Paola E.</creator><creator>Diaz-toala, Ivan</creator><creator>Cancino-Diaz, Juan C.</creator><creator>Perez-Tapia, Sonia M.</creator><creator>Cancino-Diaz, Mario E.</creator><creator>Gomez-Chavez, Fernando</creator><creator>Rodriguez-Martinez, Sandra</creator><general>Spandidos Publ Ltd</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>ABXSW</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DG8</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0002-2318-2463</orcidid><orcidid>https://orcid.org/0000-0002-2500-5954</orcidid></search><sort><creationdate>20200701</creationdate><title>Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells</title><author>Vazquez-Sanchez, Ernesto A. ; Mendoza-Figueroa, Jose S. ; Gutierrez-Gonzalez, Guadalupe ; Zapi-Colin, Luis A. ; Torales-Cardena, Azael ; Briseno-Lugo, Paola E. ; Diaz-toala, Ivan ; Cancino-Diaz, Juan C. ; Perez-Tapia, Sonia M. ; Cancino-Diaz, Mario E. ; Gomez-Chavez, Fernando ; Rodriguez-Martinez, Sandra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-4d3de9b38ba08667be431a62bb3d9899563fd45c3fb5a8c541512f74180a7a623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alefacept</topic><topic>Analysis</topic><topic>Animal models</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Antiviral drugs</topic><topic>Biological products</topic><topic>Cell adhesion</topic><topic>Cell Line</topic><topic>Cloning</topic><topic>Dendritic cells</topic><topic>Deoxyribonucleic acid</topic><topic>Disease Models, Animal</topic><topic>DNA</topic><topic>Drug development</topic><topic>E coli</topic><topic>EDTA</topic><topic>Endothelial cells</topic><topic>Endothelial Cells - cytology</topic><topic>Endothelial Cells - drug effects</topic><topic>Endothelial Cells - pathology</topic><topic>Endothelium</topic><topic>Female</topic><topic>Golimumab</topic><topic>Helper cells</topic><topic>Humans</topic><topic>Imiquimod</topic><topic>Inflammation</topic><topic>Interleukin 12</topic><topic>Interleukin 23</topic><topic>Interleukins</topic><topic>Leukocyte migration</topic><topic>Leukocytes (mononuclear)</topic><topic>Leukocytes, Mononuclear - cytology</topic><topic>Leukocytes, Mononuclear - drug effects</topic><topic>Leukocytes, Mononuclear - pathology</topic><topic>Life Sciences & Biomedicine</topic><topic>Lymphocytes T</topic><topic>Lymphoid cells</topic><topic>Macrophages</topic><topic>Medicine, Research & Experimental</topic><topic>Metastases</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monoclonal antibodies</topic><topic>Myeloid cells</topic><topic>Neutrophils</topic><topic>Oligopeptides - chemistry</topic><topic>Oligopeptides - pharmacology</topic><topic>Oligopeptides - therapeutic use</topic><topic>Oncology</topic><topic>Patients</topic><topic>Peptides</topic><topic>Phage display</topic><topic>Phototherapy</topic><topic>Proteins</topic><topic>Psoriasis</topic><topic>Psoriasis - chemically induced</topic><topic>Psoriasis - drug therapy</topic><topic>Psoriasis - pathology</topic><topic>Research & Experimental Medicine</topic><topic>Science & Technology</topic><topic>Skin</topic><topic>Therapeutic applications</topic><topic>Transendothelial and Transepithelial Migration - drug effects</topic><topic>Tumor necrosis factor</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><toplevel>online_resources</toplevel><creatorcontrib>Vazquez-Sanchez, Ernesto A.</creatorcontrib><creatorcontrib>Mendoza-Figueroa, Jose S.</creatorcontrib><creatorcontrib>Gutierrez-Gonzalez, Guadalupe</creatorcontrib><creatorcontrib>Zapi-Colin, Luis A.</creatorcontrib><creatorcontrib>Torales-Cardena, Azael</creatorcontrib><creatorcontrib>Briseno-Lugo, Paola E.</creatorcontrib><creatorcontrib>Diaz-toala, Ivan</creatorcontrib><creatorcontrib>Cancino-Diaz, Juan C.</creatorcontrib><creatorcontrib>Perez-Tapia, Sonia M.</creatorcontrib><creatorcontrib>Cancino-Diaz, Mario E.</creatorcontrib><creatorcontrib>Gomez-Chavez, Fernando</creatorcontrib><creatorcontrib>Rodriguez-Martinez, Sandra</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Linköpings universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Linköpings universitet</collection><collection>SwePub Articles full text</collection><jtitle>Molecular medicine reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vazquez-Sanchez, Ernesto A.</au><au>Mendoza-Figueroa, Jose S.</au><au>Gutierrez-Gonzalez, Guadalupe</au><au>Zapi-Colin, Luis A.</au><au>Torales-Cardena, Azael</au><au>Briseno-Lugo, Paola E.</au><au>Diaz-toala, Ivan</au><au>Cancino-Diaz, Juan C.</au><au>Perez-Tapia, Sonia M.</au><au>Cancino-Diaz, Mario E.</au><au>Gomez-Chavez, Fernando</au><au>Rodriguez-Martinez, Sandra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells</atitle><jtitle>Molecular medicine reports</jtitle><stitle>MOL MED REP</stitle><addtitle>Mol Med Rep</addtitle><date>2020-07-01</date><risdate>2020</risdate><volume>22</volume><issue>1</issue><spage>507</spage><epage>515</epage><pages>507-515</pages><issn>1791-2997</issn><issn>1791-3004</issn><eissn>1791-3004</eissn><abstract>During the progression of psoriatic lesions, abundant cellular infiltration of myeloid cells, such as macrophages and activated dendritic cells, occurs in the skin and the infiltrating cells interact with naive lymphoid cells to generate a T helper (Th)1 and Th17 environment. Therapies to treat psoriasis include phototherapy, non-steroidal and steroidal drugs, as well as antibodies to block tumor necrosis factor-alpha, interleukin (IL)-17-A and IL-12/IL-23, which all focus on decreasing the proinflammatory hallmark of psoriasis. The present study obtained the heptapeptide HP3 derived from phage display technology that blocks mononuclear cell adhesion to endothelial cells and inhibits trans-endothelial migrationin vitro. The activity of the heptapeptide in a murine model of psoriasis was also assessed, which indicated that early administration inhibited the development of psoriatic lesions. Therefore, the results suggested that HP3 may serve as a potential therapeutic target for psoriasis.</abstract><cop>ATHENS</cop><pub>Spandidos Publ Ltd</pub><pmid>32377714</pmid><doi>10.3892/mmr.2020.11128</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2318-2463</orcidid><orcidid>https://orcid.org/0000-0002-2500-5954</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1791-2997 |
| ispartof | Molecular medicine reports, 2020-07, Vol.22 (1), p.507-515 |
| issn | 1791-2997 1791-3004 1791-3004 |
| language | eng |
| recordid | cdi_proquest_journals_2409585053 |
| source | Spandidos Publications Journals; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; SWEPUB Freely available online; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Alma/SFX Local Collection |
| subjects | Alefacept Analysis Animal models Animals Antibodies Antigens Antiviral drugs Biological products Cell adhesion Cell Line Cloning Dendritic cells Deoxyribonucleic acid Disease Models, Animal DNA Drug development E coli EDTA Endothelial cells Endothelial Cells - cytology Endothelial Cells - drug effects Endothelial Cells - pathology Endothelium Female Golimumab Helper cells Humans Imiquimod Inflammation Interleukin 12 Interleukin 23 Interleukins Leukocyte migration Leukocytes (mononuclear) Leukocytes, Mononuclear - cytology Leukocytes, Mononuclear - drug effects Leukocytes, Mononuclear - pathology Life Sciences & Biomedicine Lymphocytes T Lymphoid cells Macrophages Medicine, Research & Experimental Metastases Mice Mice, Inbred BALB C Monoclonal antibodies Myeloid cells Neutrophils Oligopeptides - chemistry Oligopeptides - pharmacology Oligopeptides - therapeutic use Oncology Patients Peptides Phage display Phototherapy Proteins Psoriasis Psoriasis - chemically induced Psoriasis - drug therapy Psoriasis - pathology Research & Experimental Medicine Science & Technology Skin Therapeutic applications Transendothelial and Transepithelial Migration - drug effects Tumor necrosis factor Tumor necrosis factor-TNF Tumor necrosis factor-α |
| title | Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod-induced murine psoriasis and impedes the trans-endothelial migration of mononuclear cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T00%3A10%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Heptapeptide%20HP3%20acts%20as%20a%20potent%20inhibitor%20of%20experimental%20imiquimod-induced%20murine%20psoriasis%20and%20impedes%20the%20trans-endothelial%20migration%20of%20mononuclear%20cells&rft.jtitle=Molecular%20medicine%20reports&rft.au=Vazquez-Sanchez,%20Ernesto%20A.&rft.date=2020-07-01&rft.volume=22&rft.issue=1&rft.spage=507&rft.epage=515&rft.pages=507-515&rft.issn=1791-2997&rft.eissn=1791-3004&rft_id=info:doi/10.3892/mmr.2020.11128&rft_dat=%3Cgale_proqu%3EA629604871%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2409585053&rft_id=info:pmid/32377714&rft_galeid=A629604871&rfr_iscdi=true |